Jenburkt Pharmaceuticals has informed that with reference to the Regulation 29(1) and 30 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, a Meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, 02th June, 2021, at the Registered Office of the Company, to take on record the audited financial results for the quarter and financial year ended on 31st March 2021 and to consider recommendation of Dividend, if any. The Board will also consider a proposal to acquire a land in the state of Gujarat, to set up a modern pharmaceutical formulations manufacturing unit and authorize Director to take necessary steps in respect of the same; and to consider a proposal to begin on pilot scale to sell certain Healthcare products via digital marketing. With reference to letter no. JPL/CS/1690/2021 dated 31st March, 2020, submitted with the Exchange, on the same day, the notional trading window is closed from 1st April, 2021 up to 48 hours after the completion of Board Meeting scheduled on 2nd June, 2021.
The above information is a part of company’s filings submitted to BSE.